Phase II study on first-line treatment of NIVolumab in combination with folfoxiri/bevacizumab in patients with Advanced COloRectal cancer RAS or BRAF mutated – NIVACOR trial (GOIRC-03-2018)

Phase II study on first-line treatment of NIVolumab in combination with folfoxiri/bevacizumab in patients with Advanced COloRectal cancer RAS or BRAF mutated – NIVACOR trial (GOIRC-03-2018)

Abstract Background FOLFOXIRI (fluorouracil, leucovorin, oxaliplatin, and irinotecan) plus bevacizumab has shown to be one of the therapeutic regimens in first line with the highest activity in patients (pts.) with metastatic colorectal cancer (mCRC) unselected for biomolecular alterations. Generall...

Full description

Bibliographic Details
Main Authors: Angela Damato, Francesco Iachetta, Lorenzo Antonuzzo, Guglielmo Nasti, Francesca Bergamo, Roberto Bordonaro, Evaristo Maiello, Alberto Zaniboni, Giuseppe Tonini, Alessandra Romagnani, Annalisa Berselli, Nicola Normanno, Carmine Pinto
Format: Article
Language:English
Published: BMC 2020-08-01
Series:BMC Cancer
Subjects:
Metastatic colorectal Cancer
First line therapy
Nivolumab
FOLFOXIRI Bevacizumab
Online Access:http://link.springer.com/article/10.1186/s12885-020-07268-4

Internet

http://link.springer.com/article/10.1186/s12885-020-07268-4

Similar Items